How to buy BioLife Solutions stock

BioLife Solutions, Inc is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS) are listed on the NASDAQ and all prices are listed in US Dollars. BioLife Solutions employs 193 staff and has a trailing 12-month revenue of around 0.00.

BioLife Solutions share price

Use our graph to track the performance of BLFS stocks over time.

BioLife Solutions shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$10.31 - $47.22
50-day moving average	$35.80
200-day moving average	$36.80
Wall St. target price	$56.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.12

Buy BioLife Solutions shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BioLife Solutions stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioLife Solutions, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is BioLife Solutions under- or over-valued?

Valuing BioLife Solutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLife Solutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioLife Solutions's PEG ratio

BioLife Solutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 63.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLife Solutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioLife Solutions's EBITDA

BioLife Solutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.1 million.

The EBITDA is a measure of a BioLife Solutions's overall financial performance and is widely used to measure a its profitability.

BioLife Solutions financials

Revenue TTM	$48.1 million
Gross profit TTM	$27.9 million
Return on assets TTM	-1.11%
Return on equity TTM	2.15%
Profit margin	5.55%
Book value	$6.21
Market capitalisation	$1.2 billion

TTM: trailing 12 months

Shorting BioLife Solutions shares

There are currently 722,202 BioLife Solutions shares held short by investors – that's known as BioLife Solutions's "short interest". This figure is 27.5% down from 995,575 last month.

There are a few different ways that this level of interest in shorting BioLife Solutions shares can be evaluated.

BioLife Solutions's "short interest ratio" (SIR)

BioLife Solutions's "short interest ratio" (SIR) is the quantity of BioLife Solutions shares currently shorted divided by the average quantity of BioLife Solutions shares traded daily (recently around 382117.46031746). BioLife Solutions's SIR currently stands at 1.89. In other words for every 100,000 BioLife Solutions shares traded daily on the market, roughly 1890 shares are currently held short.

However BioLife Solutions's short interest can also be evaluated against the total number of BioLife Solutions shares, or, against the total number of tradable BioLife Solutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioLife Solutions's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioLife Solutions shares in existence, roughly 20 shares are currently held short) or 0.0296% of the tradable shares (for every 100,000 tradable BioLife Solutions shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioLife Solutions.

Find out more about how you can short BioLife Solutions stock.

BioLife Solutions share dividends

We're not expecting BioLife Solutions to pay a dividend over the next 12 months.

Have BioLife Solutions's shares ever split?

BioLife Solutions's shares were split on a 1:14 basis on 28 January 2014. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLife Solutions shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for BioLife Solutions shares which in turn could have impacted BioLife Solutions's share price.

BioLife Solutions share price volatility

Over the last 12 months, BioLife Solutions's shares have ranged in value from as little as $10.305 up to $47.215. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLife Solutions's is 1.4926. This would suggest that BioLife Solutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioLife Solutions overview

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc.

Frequently asked questions

• What percentage of BioLife Solutions is owned by insiders or institutions?

  Currently 19.05% of BioLife Solutions shares are held by insiders and 76.601% by institutions.

• How many people work for BioLife Solutions?

  Latest data suggests 193 work at BioLife Solutions.

• When does the fiscal year end for BioLife Solutions?

  BioLife Solutions's fiscal year ends in December.

• Where is BioLife Solutions based?

  BioLife Solutions's address is: 3303 Monte Villa Parkway, Bothell, WA, United States, 98021

• What is BioLife Solutions's ISIN number?

  BioLife Solutions's international securities identification number is: US09062W2044

• What is BioLife Solutions's CUSIP number?

  BioLife Solutions's Committee on Uniform Securities Identification Procedures number is: 09062W105